| Fate Therapeutics is a biopharmaceutical company. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. Co.'s other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. Co.'s allogeneic cellular immunotherapy pipeline include: ProTmune, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft. We show 28 historical shares outstanding datapoints in our FATE shares outstanding history coverage, used to compute FATE market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing FATE market cap history over the course of time is important for investors
interested in comparing FATE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of FATE versus a peer is one thing; comparing
FATE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like FATE can fluctuate over the course of history.
With this page we aim to empower investors researching FATE by allowing them to research the FATE market cap history.